Product Category:

Anti-allergic & Anti-asthmatics

Composition:

Montelukast Tablets IP (10mg)

Therapeutic Category:

Leukotriene receptor antagonist (LTRA)

Mechanism of Action:

Montelukast binds to CysLT1 receptors with high selectivity, blocking effects associated with CysLT1 receptors activation including airway bronchoconstriction, occluding mucous secretion, vascular permeability, eosinophil recruitment, and smooth muscle proliferation in asthma, as well as congested nose in allergic rhinitis. Hence, resulting in bronchodilation, reduced mucous secretion and inflammation.

Indications:

Indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients (>1 year), prevention of day and night-time symptoms in asthma, prevention of exercise-induced bronchoconstriction (EIB) in patients (> 6years), symptomatic relief of allergic rhinitis and seasonal allergic rhinitis, as an adjunctive therapy in asthma with SABA, LABA or inhaled corticosteroids.

Dosage:

For >15 years: 10 mg once daily in evening

Pack Size:

10x10s (Blisters)